DiscGenics has announced that the FDA has granted Fast Track designation for its investigational cell therapy, IDCT, currently being evaluated in regulator-allowed clinical trials in the USA and Japan for the reduction in pain and disability associated with degenerative disc disease. A press release reports that IDCT is reproducibly manufactured in a cGMP environment [...]